The study compared the effectiveness of three treatments in 214 patients with intracardiac thrombus (a blood clot in the heart): 26 patients received antiplatelet therapy, 118 patients received anticoagulant therapy, and 70 patients received combined therapy. Anticoagulation therapy was associated with a significantly lower risk of all-cause death compared with antiplatelet therapy. Anticoagulation monotherapy showed a higher probability of thrombus dissolution compared with antiplatelet therapy, although this difference was attenuated after full data adjustment. Combined treatment did not provide additional benefits compared to individual therapies in terms of thrombus dissolution or reduction in mortality. The study concluded that in patients with intracardiac thrombus, anticoagulation monotherapy is associated with significantly lower one-year mortality than antiplatelet therapy, whereas combination therapy did not provide additional benefits.